.ANALYSIS HIGHLIGHT.06 August 2024.
A large randomized regulated trial along with cisgender females highlights the difficulties of adherence to a regular oral preexposure prevention program and also demonstrates that twice-yearly shot of lenacapavir may sustain reliable HIV protection levels over 6 months.